An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology
The incidence rate of thyroid cancer (TC) has risen sharply in recent decades on a global scale. It is the most common malignant tumor of the endocrine system, accounting for 4.1% of all new cancer cases worldwide, with age-standardized incidence rates (ASIRs) of 9.1 per 100,000 in 2022, establishin...
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2025
|
| Matèries: | |
| Accés en línia: | ONIX_20250812T110751_9783725847150_595 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869528870466617344 |
|---|---|
| collection | Directory of Open Access Books |
| description | The incidence rate of thyroid cancer (TC) has risen sharply in recent decades on a global scale. It is the most common malignant tumor of the endocrine system, accounting for 4.1% of all new cancer cases worldwide, with age-standardized incidence rates (ASIRs) of 9.1 per 100,000 in 2022, establishing itself as a significant threat to population health. Although TC generally exhibits a better prognosis compared to other cancers, poorly differentiated thyroid cancer (including poorly differentiated TC,PDTC and anaplastic TC,ATC, two subtypes of TC) displays the shortest average survival time. The precise cause of TC's high incidence remains unclear, particularly the molecular mechanisms underlying its development. Consequently, the primary approaches for treating TC involve surgery, often supplemented by 131I therapy, radiotherapy, endocrine therapy, and biomarker-targeted therapy. Unfortunately, these treatments, except for targeted biological therapies, often result in irreversible harm to patients, such as thyroidectomy or radiation injuries. While targeted therapy can be expensive, and current TC biomarkers remain limited, their effects are still being explored. Additionally, aside from surgical resection, alternative treatment methods remain subject to ongoing controversy. |
| format | Online |
| id | doab-20.500.12854ir-165840 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2025 |
| publishDateRange | 2025 |
| publishDateSort | 2025 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1658402025-08-12T10:21:54Z An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology Ai, Zhilong Thyroid Carcinoma Precision Medicine Biomarkers Treatment Clinical Management Research Frontier thema EDItEUR::M Medicine and Nursing The incidence rate of thyroid cancer (TC) has risen sharply in recent decades on a global scale. It is the most common malignant tumor of the endocrine system, accounting for 4.1% of all new cancer cases worldwide, with age-standardized incidence rates (ASIRs) of 9.1 per 100,000 in 2022, establishing itself as a significant threat to population health. Although TC generally exhibits a better prognosis compared to other cancers, poorly differentiated thyroid cancer (including poorly differentiated TC,PDTC and anaplastic TC,ATC, two subtypes of TC) displays the shortest average survival time. The precise cause of TC's high incidence remains unclear, particularly the molecular mechanisms underlying its development. Consequently, the primary approaches for treating TC involve surgery, often supplemented by 131I therapy, radiotherapy, endocrine therapy, and biomarker-targeted therapy. Unfortunately, these treatments, except for targeted biological therapies, often result in irreversible harm to patients, such as thyroidectomy or radiation injuries. While targeted therapy can be expensive, and current TC biomarkers remain limited, their effects are still being explored. Additionally, aside from surgical resection, alternative treatment methods remain subject to ongoing controversy. 2025-08-12T10:21:51Z 2025-08-12T10:21:51Z 2025 book ONIX_20250812T110751_9783725847150_595 9783725847150 9783725847167 https://directory.doabooks.org/handle/20.500.12854/165840 eng image/jpeg Attribution 4.0 International https://mdpi.com/books https://mdpi.com/books/pdfview/book/11283 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-4716-7 10.3390/books978-3-7258-4716-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725847150 9783725847167 136 open access |
| spellingShingle | Thyroid Carcinoma Precision Medicine Biomarkers Treatment Clinical Management Research Frontier thema EDItEUR::M Medicine and Nursing An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology |
| title | An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology |
| title_full | An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology |
| title_fullStr | An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology |
| title_full_unstemmed | An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology |
| title_short | An Update on Mechanisms and Treatments for Thyroid Cancer in Current Oncology |
| title_sort | update on mechanisms and treatments for thyroid cancer in current oncology |
| topic | Thyroid Carcinoma Precision Medicine Biomarkers Treatment Clinical Management Research Frontier thema EDItEUR::M Medicine and Nursing |
| topic_facet | Thyroid Carcinoma Precision Medicine Biomarkers Treatment Clinical Management Research Frontier thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20250812T110751_9783725847150_595 |